Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable

Miravitlles, Marc; Soler-Cataluña, Juan José; Calle, Myriam; Molina, Jesús; Almagro, Pere; Quintano, José Antonio; Riesco, Juan Antonio; Trigueros, Juan Antonio; Pascual Piñera, Pascual; Simón, Adolfo; López-Campos, José Luis; Soriano, Joan B; Ancochea, Julio.
Arch. bronconeumol. (Ed. impr.) ; 48(7): 247-257, jul. 2012. tab, graf, ilus
Artículo en Español | IBECS (España) | ID: ibc-102734

Documentos relacionados

  1. p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics.
  2. Precision Approaches to Chronic Obstructive Pulmonary Disease Management.
  3. [The research progress of high altitude environment-associated chronic obstructive pulmonary disease and therapeutic drugs].
  4. The Role of Bioactive Small Molecules in COPD Pathogenesis.
  5. How might endotyping guide chronic obstructive pulmonary disease treatment? Current understanding, knowledge gaps and future research needs.
  6. Joint longitudinal model-based meta-analysis of FEV<sub>1</sub> and exacerbation rate in randomized COPD trials.
  7. Using UPLC-LTQ-Orbitrap-MS and HPLC-CAD to Identify Impurities in Cycloastragenol, Which Is a Pre-Clinical Candidate for COPD.
  8. [What have we learned from the German COPD cohort COSYCONET and where do we go from here?]
  9. Physiological Impairments on Respiratory Oscillometry and Future Exacerbations in Chronic Obstructive Pulmonary Disease Patients without a History of Frequent Exacerbations.
  10. Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes.